FDA Revises Its Policy on Multi-Analyte COVID-19 EUAs

The FDA has updated its policy on COVID-19 testing, clarifying that manufacturers of multi-analyte respiratory panels which include SARS-CoV-2 are now eligible for Emergency Use Authorization (EUA).
Source: The GMP Letter